Special Issues

Special Issue Title: Heart failure pathogenesis and management: heart failure with preserved ejection fraction

· Print Special Issue Flyer

· Deadline for manuscript submissions: 1 September 2021

Special Issue Editor

Guest Editor

Prof. Dr. Krishnaswami Vijayaraghavan

Institute of Congestive Heart Failure, Abrazo Arizona Heart Hospital, Phoenix , AZ , USA

Website | E-Mail

Interests: Congenital heart defects; Coronary artery disease; Heart rhythm disorders and heart failure

Special Issue Information

Dear Colleagues,

HFpEF is a complex clinical syndrome in which heart is unable to deliver adequate oxygen to the tissues required by the metabolic needs or delivers it at the expense of increased filling pressures despite a normal Ejection Fraction. Multiple comorbid conditions such as diabetes, atrial fibrillation, uncontrolled hypertension, multivessel coronary disease not amenable for intervention, morbid obesity, COPD, pulmonary hypertension, Chronic kidney disease and right heart failure are all contributing to the worsening of HFpEF. No specific treatment in clinical trials has shown to be beneficial in improving outcomes. Hence there is an urgent need to discuss the knowledge gained so far in pathophysiology, biomarkers, comorbidity management, newer therapies in diabetes management, exercise physiology and potential benefits as well as potential newer device therapies and use of technology to improve outcomes. 

Goal of this issue: 

To summarize the current knowledge in epidemiology, pathogenesis, newer biomarkers of interest in cardiorenal space, differential diagnosis and co management of concurrent conditions, discussion of current knowledge on clinical trials, role of exercise and rehab, and translate evidence from subgroups to gain newer hypothesis in innovative therapies for the future. In addition, in this era of advanced technology, there is an opportunity to discuss utilization of AI, remote technology, and Internet of Things to assess potential benefit in development of newer treatment strategies.

Prof. Dr. Krishnaswami Vijayaraghavan

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Heart failure; Congestive heart failure; Coronary artery disease; Diabetes; Obesity; Myocarditis; Prevention; Risk factors; Heart transplantation; Mechanical circulatory support

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Imaging in heart failure with preserved ejection fraction: insights into echocardiography and cardiac magnetic resonance imaging
Martin A. Chacon-Portillo, Tushar Acharya, Rajesh Janardhanan
Reviews in Cardiovascular Medicine    2021, 22 (1): 11-24.   DOI: 10.31083/j.rcm.2021.01.134
Abstract942)   HTML265)    PDF(pc) (1455KB)(1186)       Save
Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent and represents more than half of all heart failure cases. It is defined by the presence of heart failure signs and symptoms, identification of cardiac structural abnormalities leading to high left ventricular filling pressures, and an EF > 50%. Common imaging findings in HFpEF include left ventricular hypertrophy, diastolic dysfunction, left atrial enlargement, and elevated pulmonary artery pressure (> 35 mm Hg). Echocardiography is the primary imaging modality for diagnosing HFpEF. It can be complemented by cardiac magnetic resonance (CMR) when further characterization is needed. Advances like real-time 3-dimensional echocardiography and speckle-tracking derived strain, as well as tissue characterization by CMR, have furthered our understanding of the mechanisms and aided in making the diagnosis of a diverse group of conditions that can present as HFpEF. This review aims to touch upon the imaging methods of characterizing HFpEF and discuss their role in specific disease entities.
Related Articles | Metrics
Epidemiology and pathogenesis of heart failure with preserved ejection fraction
Nandini Nair
Reviews in Cardiovascular Medicine    2020, 21 (4): 531-540.   DOI: 10.31083/j.rcm.2020.04.154
Abstract1760)   HTML272)    PDF(pc) (312KB)(2770)       Save
Heart failure (HF) is a complex syndrome that affects approximately 6.5 million adults in the United States. About half of the 6.5 million adults with HF are estimated to be individuals with heart failure with preserved ejection fraction (HFpEF). It is a common cause for poor quality of life, increased health-care resource utilization, and early mortality. HF incidence has risen to epidemic proportions in the recent years. This review attempts to address the epidemiology and pathophysiology of HFpEF. The incidence of HFpEF increased from 48% to 57% from 2000 to 2007 with a slight decrease in 2010 to 52%. The temporal trends in heart failure show an overall stable incidence of HF over the last two decades with increasing incidence of HFpEF and decreasing HFrEF incidence. Many etiologies contribute to the development of HFpEF which makes the treatment very challenging. Pathophysiology of HFpEF is multifaceted stemming from several disease-specific aspects of inflammation and endothelial function, cardiomyocyte hypertrophy and fibrosis, ventricular-vascular uncoupling, pulmonary hypertension and chronotropic incompetence. Hence identifying the risk factors and etiologies is imperative to achieve optimal outcomes in this population. Newer insights into myocardial remodeling have led to an interesting finding of abnormal fibroblasts in HFpEF which are apoptosis resistant and initiate the development of an abnormal myocardial matrix resulting in initiation and progression of the disease. Upregulation of ROS has also been implicated in HFpEF. Further investigation could provide new avenues to target therapeutics specifically to stop initiation and progression of fibrosis.
Related Articles | Metrics
Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction
Nidhi Madan, Dinesh Kalra
Reviews in Cardiovascular Medicine    2020, 21 (2): 181-190.   DOI: 10.31083/j.rcm.2020.02.65
Abstract789)   HTML49)    PDF(pc) (1113KB)(1819)       Save
Heart failure with preserved ejection fraction is a very common clinical problem. Its prevalence is increasing with aging of the population. A diverse group of risk factors and etiologies comprise the HFpEF syndrome. No specific therapies have been shown to improve survival for the vast majority of HFpEF cases. Restrictive cardiomyopathies account for a significant portion of HFpEF patients and are characterized by diastolic dysfunction due to infiltration of the myocardium or ventricular hypertrophy. Many of these restrictive diseases occur in the context of myocardial infiltration by other substances such as amyloid, iron or glycogen or endomyocardial fibrosis. These infiltrative diseases usually have important clues in the clinical picture and on cardiac imaging that may allow differentiation from the usual HFpEF phenotype (that is commonly seen in the older, hypertensive patient). Noninvasive diagnosis has replaced endomyocardial biopsy for most instances in the workup of these conditions. Early recognition is important to institute specific therapies and to improve prognosis. In this review, we describe 4 major infiltrative cardiomyopathies (Cardiac Amyloidosis, Sarcoidosis, Hemochromatosis and Fabry disease), and their key imaging features.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3